Table 2.
Prior treatments for prostate cancer in phase II
| Parameter | Category/statistic | Phase II (N = 38) |
|---|---|---|
| Cancer treatment history, radiation | Yes | 19 (50.0 %) |
| Cancer treatment history, procedure | Yes | 6 (15.8 %) |
| Quantity of prior hormone therapy linesa | 3 | 3 (7.9 %) |
| 4 | 5 (13.2 %) | |
| 5 | 13 (34.2 %) | |
| 6 | 11 (28.9 %) | |
| ≥7 | 6 (15.8 %) | |
| Typical prior hormone therapy, other than GnRH analogue | Bicalutamide | 38 (100.0 %) |
| Flutamide | 29 (76.3 %) | |
| Estramustine | 30 (78.9 %) | |
| Docetaxel | 38 (100 %) | |
| Number of prior chemotherapy regimens | 1 | 8 (21.1 %) |
| 2 | 30 (78.9 %) | |
| Duration of prior docetaxel (days) | Median | 198 |
| Min–max | 1–1012 |
GnRH gonadotropin-releasing hormone
aSum of prior hormonal treatment agents including castration therapy